| Income Statement | 2025-02-23 | 2024-11-24 | ||
|---|---|---|---|---|
| (loss) income from continuing operations before income taxes | -14,777 | -6,528 | ||
| Income tax benefit (expense) | -8 | 43 | ||
| (loss) income from continuing operations | -14,769 | -6,571 | ||
| Net (loss) income | -14,769 | -6,571 | ||
| Accretion of preferred stock to redemption value | 144 | - | ||
| Fair value of conversion ratio improvement to preferred stockholders | - | 2,132 | ||
| Preferred stock dividends | 2,466 | - | ||
| (loss) income available to common stockholders | -17,379 | -8,703 | ||
| Basic eps | -0.47 | -0.25 | ||
| Diluted eps | -0.47 | -0.25 | ||
| Basic average shares | 37,020,570 | 34,360,657 | ||
| Diluted average shares | 37,020,570 | 34,360,657 | ||
LIFECORE BIOMEDICAL, INC. DE (LFCR)
LIFECORE BIOMEDICAL, INC. DE (LFCR)